MALTOMA presenting with thrombocytopenia

• Published in: American journal of clinical oncology Vol. 28; no. 3; p. 321
• Main Authors: Sakalli, Hakan, Akcali, Zafer, Kayaselcuk, Fazilet, Ozyilkan, Ozgur
• Format: Journal Article
• Language: English
• Published: United States 01.06.2005
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow - pathology; Cyclophosphamide - administration & dosage; Diarrhea - etiology; Doxorubicin - administration & dosage; Duodenal Neoplasms - complications; Duodenal Neoplasms - drug therapy; Duodenal Neoplasms - pathology; Female; Humans; Immunoglobulins, Intravenous - therapeutic use; Lymphoma, B-Cell, Marginal Zone - complications; Lymphoma, B-Cell, Marginal Zone - drug therapy; Lymphoma, B-Cell, Marginal Zone - pathology; Methylprednisolone - therapeutic use; Prednisone - administration & dosage; Remission Induction; Stomach Neoplasms - complications; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Thrombocytopenia - drug therapy; Thrombocytopenia - etiology; Thrombocytopenia - immunology; Vincristine - administration & dosage
• ISSN: 1537-453X
• DOI: 10.1097/01.coc.0000144263.32248.1a

Immune thrombocytopenia of malignancy is most frequently associated with lymphoproliferative disorders. Thrombocytopenia generally does not develop in MALT subtype of lymphoma (MALTOMA) unless the tumor has infiltrated the bone marrow. Cytopenias resulting from immunologic causes in patients with MALT lymphoma were rarely reported in the literature. In this report, a woman was diagnosed with stage IIE gastrointestinal MALTOMA. Bone marrow infiltration was not present. Patient also had thrombocytopenia, which did not improve after intravenous steroid treatment. Thrombocyte count increased after a single gamma-globulin infusion, and 6 cycles of chemotherapy were given every 21 days. The patient has remained in complete remission.